GlassScriptPhysician profile
Timothy A Edgil
NPI 1699236968
$9,828.47
in general payments reported to CMS, 2019-2025
24 companies · $8,436 in 2025
The $8,436 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $118 · 2024: $1,149 · 2025: $8,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,091 · Consulting Fee: $3,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,090.97 |
| Consulting Fee | $3,612.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,472.30 | 2024-2025 | |
| Amgen INC. | $1,419.46 | 2024-2025 | Uplizna, Evenity, Prolia |
| Abbvie INC. | $1,111.61 | 2024-2025 | |
| Glaxosmithkline, LLC. | $419.36 | 2023-2025 | Benlysta |
| Ucb, INC. | $359.07 | 2024-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $324.24 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $308.56 | 2024-2025 | Acthar |
| Pfizer INC. | $254.33 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.19 | 2024-2025 | Ofev |
| Janssen Biotech, INC. | $160.26 | 2025 | Tremfya |
| Radius Health, INC. | $154.97 | 2024-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $153.07 | 2024-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $152.24 | 2022-2024 | Strensiq |
| Lilly USA, LLC | $61.76 | 2024-2025 | Taltz |
| Aurinia Pharma U.S., INC. | $52.88 | 2024-2025 | Lupkynis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $41.21 | 2025 | Hadlima |
| Octapharma USA, INC. | $40.89 | 2024 | Octagam Immune Globulin (Human) |
| Abbott Laboratories | $24.85 | 2025 | Eterna |
| Genentech USA, INC. | $24.13 | 2025 | Gazyva |
| Fresenius Kabi USA, LLC | $20.70 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.64 | 2025 | Tremfya |
| Bioventus LLC | $16.41 | 2024 | Durolane |
| E.R. Squibb & Sons, L.L.C. | $15.11 | 2025 | Orencia |
| Kyowa Kirin, INC. | $13.23 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Edgil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.